文献速递临床试验与 GCP

关节腔内注射富血小板血浆与安慰剂对膝骨关节炎患者疼痛及内侧胫骨软骨体积的影响:RESTORE随机临床试验

Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

这项随机、双组、安慰剂对照、参与者与注射者及评估者设盲的临床试验纳入288例有症状的内侧膝骨关节炎(Kellgren和Lawrence 2或3级)患者,比较每周一次共3次关节腔内注射贫白细胞富血小板血浆(PRP)与生理盐水安慰剂的疗效。12个月时,PRP组与安慰剂组膝关节疼痛评分平均变化分别为-2.1分与-1.8分(差值-0.4分,95%CI -0.9至0.2,P=0.17),内侧胫骨软骨体积平均变化分别为-1.4%与-1.2%(差值-0.2%,95%CI -1.9%至1.5%,P=0.81),31项预设次要结局中29项无显著组间差异。结论认为PRP与生理盐水安慰剂相比在12个月时对症状或关节结构无显著差异,这些发现不支持将PRP用于膝骨关节炎的管理。

要点

  • 12个月时PRP组与安慰剂组膝关节疼痛评分平均变化分别为-2.1分与-1.8分,差值-0.4分(95%CI -0.9至0.2,P=0.17)。
  • 12个月时PRP组与安慰剂组内侧胫骨软骨体积平均变化分别为-1.4%与-1.2%,差值-0.2%(95%CI -1.9%至1.5%,P=0.81)。
  • 31项预设次要结局中29项无显著组间差异。

核心结论

  • 在有症状的轻至中度影像学膝骨关节炎患者中,与生理盐水安慰剂注射相比,关节腔内注射PRP在12个月时对症状或关节结构未产生显著差异。
  • 这些发现不支持将PRP用于膝骨关节炎的管理。

研究设计与样本

  • 随机、双组、安慰剂对照、参与者与注射者及评估者设盲的临床试验,纳入社区来源的288例50岁及以上有症状的内侧膝骨关节炎(Kellgren和Lawrence 2或3级)患者。
  • 研究在澳大利亚悉尼和墨尔本进行,招募时间为2017年8月24日至2019年7月5日,12个月随访于2020年7月22日完成。
  • 干预为每周一次共3次关节腔内注射,使用市售贫白细胞PRP产品(144例参与者)或生理盐水安慰剂(144例参与者)。

主要发现

  • 12个月时PRP组与安慰剂组膝关节疼痛评分(11分制,0-10分,评分越高疼痛越重,最小临床重要差异为1.8)平均变化分别为-2.1分与-1.8分,差值-0.4分(95%CI -0.9至0.2分,P=0.17)。
  • 12个月时PRP组与安慰剂组内侧胫骨软骨体积平均变化分别为-1.4%与-1.2%,差值-0.2%(95%CI -1.9%至1.5%,P=0.81)。
  • 31项预设次要结局(25项症状相关和6项MRI评估,最小临床重要差异未知)中29项无显著组间差异,评估疼痛、功能、生活质量、总体变化和关节结构。
  • 288例随机化参与者平均年龄61.9岁(SD 6.5),女性169例(59%),269例(93%)完成试验,两组各有140例参与者(97%)接受全部3次注射。

临床怎么用

  • 原文结论指出这些发现不支持将PRP用于膝骨关节炎的管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Most clinical guidelines do not recommend platelet-rich plasma (PRP) for knee osteoarthritis (OA) because of lack of high-quality evidence on efficacy for symptoms and joint structure, but the guidelines emphasize the need for rigorous studies. Despite this, use of PRP in knee OA is increasing. OBJECTIVE: To evaluate the effects of intra-articular PRP injections on symptoms and joint structure in patients with symptomatic mild to moderate radiographic medial knee OA. DESIGN, SETTING, AND PARTICIPANTS: This randomized, 2-group, placebo-controlled, participant-, injector-, and assessor-blinded clinical trial enrolled community-based participants (n = 288) aged 50 years or older with symptomatic medial knee OA (Kellgren and Lawrence grade 2 or 3) in Sydney and Melbourne, Australia, from August 24, 2017, to July 5, 2019. The 12-month follow-up was completed on July 22, 2020. INTERVENTIONS: Interventions involved 3 intra-articular injections at weekly intervals of either leukocyte-poor PRP using a commercially available product (n = 144 participants) or saline placebo (n = 144 participants). MAIN OUTCOMES AND MEASURES: The 2 primary outcomes were 12-month change in overall average knee pain scores (11-point scale; range, 0-10, with higher scores indicating worse pain; minimum clinically important difference of 1.8) and percentage change in medial tibial cartilage volume as assessed by magnetic resonance imaging (MRI). Thirty-one secondary outcomes (25 symptom related and 6 MRI assessed; minimum clinically important difference not known) evaluated pain, function, quality of life, global change, and joint structures at 2-month and/or 12-month follow-up. RESULTS: Among 288 patients who were randomized (mean age, 61.9 [SD, 6.5] years; 169 [59%] women), 269 (93%) completed the trial. In both groups, 140 participants (97%) received all 3 injections. After 12 months, treatment with PRP vs placebo injection resulted in a mean change in knee pain scores of -2.1 vs -1.8 points, respectively (difference, -0.4 [95% CI, -0.9 to 0.2] points; P = .17). The mean change in medial tibial cartilage volume was -1.4% vs -1.2%, respectively (difference, -0.2% [95% CI, -1.9% to 1.5%]; P = .81). Of 31 prespecified secondary outcomes, 29 showed no significant between-group differences. CONCLUSIONS AND RELEVANCE: Among patients with symptomatic mild to moderate radiographic knee OA, intra-articular injection of PRP, compared with injection of saline placebo, did not result in a significant difference in symptoms or joint structure at 12 months. These findings do not support use of PRP for the management of knee OA. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry Identifier: ACTRN12617000853347.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Bennell KL, Paterson KL, Metcalf BR, et al. Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA. 2021. PMID: 34812863. doi:10.1001/jama.2021.19415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。